Biohaven OCD Study

Summary

This research study is investigating a new study medication as a possible treatment for Obsessive Compulsive Disorder (OCD). Biohaven Pharmaceuticals, Inc. is sponsoring this research study.

Obsessive Compulsive Disorder is a pattern of unreasonable thoughts and fears (obsessions) that can lead to repetitive behaviors (compulsions). These obsessions and compulsions can interfere with daily activities. Up to 60% of patients with OCD do not have an effective response to current medication treatments.

The study may be an effective adjunct to a person's current treatment regime.

Eligibility

Currently recruiting participants: Yes

Eligible gender: Male, Female

Eligible ages: 18 to 65

Inclusion criteria:

Male and female outpatients.
Ages 18-65
Diagnosed with OCD.
Not responding adequately to current medications.

Exclusion criteria:

Acute suicidality, suicide attempt or self-injurious behaviour in the last 12 months.
History of psychosurgery, Deep Brain Stimulation (DBS) or Electroconvulsive Therapy (ECT)
History of substance use disorder in the last 12 months, with the exception of tobacco.
History of eating disorder within the last 12 months.
Prior or current unstable medical condition.
Disallowed medications. (to be reviewed by study team)
Women who are pregnant, nursing or who plan to become pregnant while in the trial. History of Type I or Type II insulin-dependent diabetes Mellitus.

Participate

Fill out the following form if you want to participate in this research

Method of contact

Collection of personal information
Your personal information is collected under the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If you have any questions about the collection or use of this information, please visit our Access to Information page.

Additional information

Contact information

Mental Health Clinical Trials Unit University of Calgary Mathison Centre for Mental Health Research & Education TRW Building, 1st floor 403-210-6904 aunshu.goyal@ucalgary.ca

Principal investigator:

Paul Arnold

Clinical trial:

Yes

REB-ID:

REB21-0310